ReviewDrugs2005
Infliximab: in ankylosing spondylitis.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.Rheumatology international · 2007Trial
- Global research status and trends in the treatment of ankylosing spondylitis from 2005 to 2024: a bibliometric analysis.Clinical rheumatology · 2026Review
- DBI Mediates the Progression of Ankylosing Spondylitis by Regulating CD56Analytical cellular pathology (Amsterdam) · 2025Article
- Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database.Frontiers in pharmacology · 2024Article
- A descriptive analysis of real-world treatment patterns of innovator (RemicadeBiologics : targets & therapy · 2018Article
- Management of ankylosing spondylitis with infliximab.Open access rheumatology : research and reviews · 2009Review
- Infliximab in the treatment of Crohn's disease.Therapeutics and clinical risk management · 2007Article
- Clinical pharmacokinetics and use of infliximab.Clinical pharmacokinetics · 2007Review
- Review
- A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infliximab is a monoclonal antibody that binds to tumour necrosis factor-alpha and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn's disease and ankylosing spondylitis.black triangle In well designed, placebo-controlled trials of 12 or 24 weeks' duration in patients with active ankylosing spondylitis, more infliximab 5 mg/kg recipients achieved a response than placebo recipients according to Ankylosing Spondylitis Assessment Study 20% (61.2% vs 19.2%) or Bath Ankylosing Spondylitis Disease Activity Index 50% (53% vs 9%) criteria (primary endpoints). black triangle Infliximab was also superior to placebo in terms of various secondary clinical endpoints and in reducing spinal inflammation (as assessed by magnetic resonance imaging).black triangle Prolonged efficacy has been demonstrated in patients with ankylosing spondylitis who received infliximab for up to 3 years.black triangle Infliximab is generally well tolerated in patients with ankylosing spondylitis, with most adverse events being of mild-to-moderate severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.